Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RepliCel Life Sciences Inc. (REPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.20590.0000 (0.00%)
At close: 12:27PM EST
Advertisement

RepliCel Life Sciences Inc.

570 Granville Street
Suite 900
Vancouver, BC V6C 3P1
Canada
604 248 8730
https://www.replicel.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. R. Lee Buckler B.Ed., L.L.B., LLBPres, CEO, Corp. Sec. & Director188.2kN/A1966
Mr. Simon S. Ma CPA, B.A., CACFO & Director of Fin.75.28kN/A1965
Dr. Kevin John McElwee Ph.D.Chief Scientific Officer23.52kN/A1970
Mr. Darrell Panich M.Sc, PMP, CPMClinical ConsultantN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

Corporate Governance

RepliCel Life Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement